Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
Sydney Australia, 11 April 2022: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted Patent Family 3 “Anti-Virus Agent and Method for Treatment of Viral Infection”, furthering marketing and manufacturing monopolies to February 2037.
The Intellectual Property Department of the Hong Kong Special Administrative Region has granted claims relating to RECCE® 327 (R327) and Anti-Viral formulation RECCE® 529 (R529), most notably:
- Composition/method of manufacture of RECCE® anti-infectives
- Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses
- Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
The pharmaceutical market in Hong Kong is valued at USD $2.3 billion, with rising demand for chronic disease treatment.[1]
Chief Executive Officer, James Graham said: “We continue to build our patent portfolio in key geographies and major medical markets. This newly granted patent by the Hong Kong Special Administrative Region of the People's Republic of China is another endorsement for our commercial and clinical development strategy highlighting the potential of our Australian anti-infective technology”
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
[1] https://www.pacificbridgemedical.com/target-asian-markets/hong-kong-medical-market/
